These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26319115)

  • 21. Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.
    Vaduganathan M; Butler J; Gheorghiade M
    Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27707750
    [No Abstract]   [Full Text] [Related]  

  • 22. What's next after 50 years of psychiatric drug development: an FDA perspective.
    Laughren TP
    J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The complexity of integrating speed and safety in drug development and approval.
    Charo RA
    JAMA Intern Med; 2013 Jul; 173(13):1165-6. PubMed ID: 23568604
    [No Abstract]   [Full Text] [Related]  

  • 24. Prospects for rapid advances in the development of new medicines for special medical needs.
    Milne CP
    Clin Pharmacol Ther; 2014 Jan; 95(1):98-109. PubMed ID: 23917473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Status and thoughts of Chinese patent medicines seeking approval in the US market.
    Lei X; Chen J; Liu CX; Lin J; Lou J; Shang HC
    Chin J Integr Med; 2014 Jun; 20(6):403-8. PubMed ID: 24952167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Issues and promise in clinical studies of botanicals with anticonvulsant potential.
    Ekstein D
    Epilepsy Behav; 2015 Nov; 52(Pt B):329-32. PubMed ID: 26341963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Development for Asthma and COPD: A Regulatory Perspective.
    Mann M; Meyer RJ
    Respir Care; 2018 Jun; 63(6):797-817. PubMed ID: 29794212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 29. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers.
    Yamashita K; Kaneko M; Narukawa M
    Clin Pharmacol Ther; 2019 Jan; 105(1):153-160. PubMed ID: 29882302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of the use of botanicals for epilepsy in complementary medical systems--Traditional Chinese Medicine.
    Xiao F; Yan B; Chen L; Zhou D
    Epilepsy Behav; 2015 Nov; 52(Pt B):281-9. PubMed ID: 26052078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2014 Jun; 30(5):371-2. PubMed ID: 24897062
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug development: current challenges and federal initiatives.
    Strawbridge S; Hobbs L
    Conn Med; 2014; 78(10):595-600. PubMed ID: 25745738
    [No Abstract]   [Full Text] [Related]  

  • 34. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):701. PubMed ID: 24073621
    [No Abstract]   [Full Text] [Related]  

  • 35. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of probiotics as biologic drugs.
    Hoffman FA
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S125-7; discussion S144-51. PubMed ID: 18181717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
    Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementing the Biopharmaceutics Classification System in Drug Development: Reconciling Similarities, Differences, and Shared Challenges in the EMA and US-FDA-Recommended Approaches.
    Cardot JM; Garcia Arieta A; Paixao P; Tasevska I; Davit B
    AAPS J; 2016 Jul; 18(4):1039-46. PubMed ID: 27116020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory toxicology perspectives on the development of botanical drug products in the United States.
    Wu KM; Farrelly J; Birnkrant D; Chen S; Dou J; Atrakchi A; Bigger A; Chen C; Chen Z; Freed L; Ghantous H; Goheer A; Hausner E; Osterberg R; Rhee H; Zhang K
    Am J Ther; 2004; 11(3):213-7. PubMed ID: 15133537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.